Premium
Cysteine‐rich secretory protein 3 and β‐microseminoprotein on prostate cancer needle biopsies do not have predictive value for subsequent prostatectomy outcome
Author(s) -
Hoogland Agnes Marije,
Dahlman Anna,
Vissers Kees J.,
Wolters Tineke,
Schröder Fritz H.,
Roobol Monique J.,
Bjartell Anders S.,
van Leenders Geert J.L.H.
Publication year - 2011
Publication title -
bju international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.773
H-Index - 148
eISSN - 1464-410X
pISSN - 1464-4096
DOI - 10.1111/j.1464-410x.2010.10059.x
Subject(s) - prostatectomy , prostate cancer , medicine , prostate , biopsy , immunohistochemistry , urology , prostate specific antigen , stage (stratigraphy) , cancer , pathology , oncology , biology , paleontology
What’s known on the subject? and What does the study add? Cysteine‐rich secretory protein 3 (CRISP‐3) and β‐microseminoprotein (β‐MSP) both have independent prognostic value for biochemical recurrence of prostate cancer after radical prostatectomy. The study investigates whether CRISP‐3 and β‐MSP have prognostic value on diagnostic prostate needle‐biopsies, which are more relevant for therapeutic decision‐making. On needle‐biopsies CRISP‐3 and β‐MSP do not have significant prognostic value. OBJECTIVES • To investigate whether cysteine‐rich secretory protein 3 (CRISP‐3) and/or β‐microseminoprotein (β‐MSP) expression in diagnostic prostate needle biopsies have predictive value for prostate cancer (PC) on radical prostatecomy (RP). • To evaluate their potential clinical implementation in a preoperative setting. PATIENTS AND METHODS • In total, 174 participants from the European Randomized Study of Screening for Prostate Cancer, Rotterdam section, treated by RP for PC were included in the present study. • CRISP‐3 and β‐MSP immunohistochemistry was performed on corresponding diagnostic needle biopsies. • Outcome was correlated with clinicopathological parameters (prostate‐specific‐antigen, PSA; number of positive biopsies; Gleason score, GS; pT‐stage; surgical margins at RP) and significant PC at RP (pT3/4, or GS > 6, or tumour volume ≥0.5 mL) in the total cohort ( n = 174) and in a subgroup with low‐risk features at biopsy (PSA ≤ 10 ng/ml, cT ≤ 2, PSA density <0.20 ng/mL/g, GS < 7 and ≤2 positive biopsy cores; n = 87). RESULTS • β‐MSP and CRISP‐3 expression in PC tissue was heterogeneous, with variable staining intensities occurring in the same tissue specimen. • High expression of β‐MSP significantly correlated with GS < 7 at RP; it was not a predictor for significant PC at RP neither in the total group ( n = 174; odds ratio, OR, 0.319; 95% confidence interval, CI, 0.060–1.695; P = 0.180), nor in the low‐risk group ( n = 87; OR, 0.227; 95% CI, 0.040–1.274; P = 0.092). • CRISP‐3 expression was not related to clinicopathological parameters, and did not predict significant PC at RP in the total group ( n = 174; OR, 1.056; 95% CI, 0.438–2.545; P = 0.904) or the low‐risk group ( n = 87; OR, 1.856; 95% CI, 0.626–5.506; P = 0.265). CONCLUSIONS • High β‐MSP expression correlated with low GS in subsequent RP specimens, supporting the view that β‐MSP exerts a tumour‐suppressive effect. • No significant prognostic value of β‐MSP or CRISP‐3 in prostate needle biopsies for significant PC at RP was found. • β‐MSP or CRISP‐3 do not have additional value in the therapeutic stratification of patients with PC.